Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lois Shepherd

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyRobert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupLaurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Leukemia & Lymphoma|June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Biopreservation and Biobanking|May 22, 2014
Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet)Elizabeth A M Matzke, Sheila O'Donoghue, Rebecca O Barnes, et al.
British Journal of Haematology|October 11, 2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10Michael J Kovacs, Gwynivere A Davies, Judy-Anne W Chapman, et al.
Blood|October 24, 2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman, Janet W Andersen, Charles A Schiffer, et al.
JCO Clinical Cancer Informatics|November 27, 2023
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data SetsSamer El Kababji, Nicholas Mitsakakis, Xi Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Leukemia Research|March 27, 2013
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129Dan Douer, Lynette N Zickl, Charles A Schiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2013
Mammographic breast density response to aromatase inhibitionCeline M Vachon, Vera J Suman, Kathleen R Brandt, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyRobert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupLaurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Leukemia & Lymphoma|June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Biopreservation and Biobanking|May 22, 2014
Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet)Elizabeth A M Matzke, Sheila O'Donoghue, Rebecca O Barnes, et al.
British Journal of Haematology|October 11, 2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10Michael J Kovacs, Gwynivere A Davies, Judy-Anne W Chapman, et al.
Blood|October 24, 2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman, Janet W Andersen, Charles A Schiffer, et al.
JCO Clinical Cancer Informatics|November 27, 2023
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data SetsSamer El Kababji, Nicholas Mitsakakis, Xi Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Leukemia Research|March 27, 2013
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129Dan Douer, Lynette N Zickl, Charles A Schiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2013
Mammographic breast density response to aromatase inhibitionCeline M Vachon, Vera J Suman, Kathleen R Brandt, et al.
Pageof 10